Melissa Champe-Seagle, MD
Internal Medicine · Mocksville, NCNPI 1992797781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Pfizer at 31.2% of the total. Reporting peaked in 2020 at $834 and has fallen 98.3% since, to $14 in 2024.
Across 247 payments — averaging $13.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Lilly USA, LLC$297
- Novo Nordisk$153
- Boehringer Ingelheim$146
- Ironwood Pharmaceuticals, Inc$145
- AstraZeneca$140
- plus $1K from 27 others
Across 4 payments — averaging $21,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$87K
What the payments were for
- Food & beverage$3,26399%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 100 | $1,028 |
| Lilly USA, LLC | 23 | $297 |
| Novo Nordisk | 10 | $153 |
| Boehringer Ingelheim | 10 | $146 |
| Ironwood Pharmaceuticals, Inc | 9 | $145 |
| AstraZeneca | 10 | $140 |
| Sanofi-aventis U.S. LLC | 8 | $137 |
| GSK | 9 | $135 |
| Novartis | 8 | $122 |
| Bayer | 7 | $105 |
| AbbVie(2 entities) | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $93 |
| Merck | 6 | $83 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81 |
| Abbott | 3 | $72 |
| Amarin Pharma, Inc. | 4 | $69 |
| IBSA Pharma Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Shield Therapeutics Inc | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$3,293 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArexvyRsvpref3 Antigen/As01e/Pf | 303 | $93,745 |
| EliquisApixaban | 91 | $76,076 |
| MounjaroTirzepatide | 50 | $65,958 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 264 | $59,315 |
| XareltoRivaroxaban | 39 | $33,847 |
| OzempicSemaglutide | 28 | $32,094 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,943 |
| JanuviaSitagliptin Phosphate | 21 | $15,061 |
| JardianceEmpagliflozin | 14 | $13,323 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,170 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 161 | $11,337 |
| MyrbetriqMirabegron | 16 | $10,771 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,066 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 153 | $3,697 |
| Omeprazole | 179 | $3,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArexvy, Shingrix, Trelegy Ellipta | $135 | $170,003587 claims |
| PfizerEliquis, Prempro | $1,028 | $79,035104 claims |
| Lilly USA, LLCMounjaro | $297 | $65,95850 claims |
| Johnson & JohnsonXarelto | $16 | $33,84739 claims |
| Novo NordiskOzempic | $153 | $32,09428 claims |
| MerckJanuvia | $83 | $15,06121 claims |
| Boehringer IngelheimJardiance | $146 | $13,32314 claims |
| AstraZenecaSymbicort | $140 | $7,06620 claims |
| AbbVieSynthroid | $98 | $1,84024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Mocksville
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.